Curcumin prevents aggregation in α-synuclein by increasing reconfiguration rate.
about
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Diseasen-butylidenephthalide protects against dopaminergic neuron degeneration and α-synuclein accumulation in Caenorhabditis elegans models of Parkinson's diseaseCuminaldehyde as the Major Component of Cuminum cyminum, a Natural Aldehyde with Inhibitory Effect on Alpha-Synuclein Fibrillation and CytotoxicityEffects of Mutations on the Reconfiguration Rate of α-SynucleinStructural determinants of Tau aggregation inhibitor potencyCurcumin Pyrazole and its derivative (N-(3-Nitrophenylpyrazole) Curcumin inhibit aggregation, disrupt fibrils and modulate toxicity of Wild type and Mutant α-SynucleinMolecular basis for preventing α-synuclein aggregation by a molecular tweezer.Biochemical stabilization of glucagon at alkaline pH.Curcumin prevents formation of polyglutamine aggregates by inhibiting Vps36, a component of the ESCRT-II complex.Interaction of multimicrobial synthetic inhibitor 1,2-bis(2-benzimidazolyl)-1,2-ethanediol with serum albumin: spectroscopic and computational studies.Investigation of the interaction of naringin palmitate with bovine serum albumin: spectroscopic analysis and molecular docking.Structure and mechanism of action of tau aggregation inhibitors.Curcumin Treatment Improves Motor Behavior in α-Synuclein Transgenic MiceSmall Molecules Detected by Second-Harmonic Generation Modulate the Conformation of Monomeric α-Synuclein and Reduce Its Aggregation in CellsNatural biomolecules and protein aggregation: emerging strategies against amyloidogenesisα-Synuclein oligomers and clinical implications for Parkinson disease.Understanding protein aggregation from the view of monomer dynamicsFasudil attenuates aggregation of α-synuclein in models of Parkinson's diseaseProtein folding and aggregation into amyloid: the interference by natural phenolic compoundsPotential Role of Caffeine in the Treatment of Parkinson's Disease.α-Synuclein misfolding assessed with single molecule AFM force spectroscopy: effect of pathogenic mutations.Naturally occurring plant polyphenols as potential therapies for inherited neuromuscular diseases.Monoamine oxidase and α-synuclein as targets in Parkinson's disease therapy.Natural polyphenols binding to amyloid: a broad class of compounds to treat different human amyloid diseases.The roughness of the protein energy landscape results in anomalous diffusion of the polypeptide backbone.Clinical development of curcumin in neurodegenerative disease.Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.Effects of hesperidin, a flavanone glycoside interaction on the conformation, stability, and aggregation of lysozyme: multispectroscopic and molecular dynamic simulation studies?Curcumin modulates α-synuclein aggregation and toxicity.Curcumin ameliorates the neurodegenerative pathology in A53T α-synuclein cell model of Parkinson's disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy.Effect of curcumin analogs onα-synuclein aggregation and cytotoxicity.Effects of 2-amino-8-hydroxyquinoline interaction on the conformation of physiological isomers of human serum albumin.Therapeutic Effects of CUR-Activated Human Umbilical Cord Mesenchymal Stem Cells on 1-Methyl-4-phenylpyridine-Induced Parkinson's Disease Cell Model.Prion protein dynamics before aggregation.How curcumin affords effective protection against amyloid fibrillation in insulin.Metal chelator EGCG attenuates Fe(III)-induced conformational transition of α-synuclein and protects AS-PC12 cells against Fe(III)-induced death.Investigation of the effects of carbon-based nanomaterials on A53T alpha-synuclein aggregation using a whole-cell recombinant biosensor.Curcumin affords neuroprotection and inhibits α-synuclein aggregation in lipopolysaccharide-induced Parkinson's disease model.Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form.Protective effects of curcumin against rotenone-induced rat model of Parkinson's disease: in vivo electrophysiological and behavioral study.
P2860
Q26739412-803005D1-F923-48FF-809E-1B877DCAFA11Q27334018-CCC3F25A-2004-4AD2-BF8A-134E04A24B63Q28267154-53898FC5-33FE-4598-9E6F-44953A5FC031Q28834531-CA28D1C3-2707-41CA-AB5A-305CF31A77D8Q30353954-02D03C34-96D4-46A0-950E-0AB1549A6053Q30410869-7F13A2C2-234A-4479-B410-78EC81BC7BEAQ33675844-13C7C01F-780F-47A9-A070-60B2CDA068CCQ34360882-56746BA0-ADAB-4EAA-B298-7A651485494EQ34374859-B1278A49-BC05-461C-A44E-D6155D040E78Q34545134-6DAFBA59-E8C7-4D0A-8C3D-4B3CA9F8A0C6Q34634657-652FB4A1-EABE-4D5E-AD6C-4EB355D0EB83Q34902096-6A6C9457-6210-4729-BBB7-3C7C9CC18534Q35650069-CEEFF189-75A0-4AB2-A55C-D2D65BCB5801Q35784396-7BBCC1EE-2F0C-4597-AE16-8982A91E753CQ36538570-2832BEBE-5535-44D2-89DB-53F3E49ADCEDQ36718306-170FA884-F0E0-497E-A441-FEEEE47AA6CCQ36806901-09D747D7-1DAE-42FF-A952-2C1CCDA315ECQ36825541-EAEAAE73-3287-42A4-889A-B0E4C0B7A9A1Q37007345-80657D18-9A44-4D1A-B825-C575C88B68C5Q37129378-13409C9B-36FC-4979-9A8D-55BF4DA8815EQ37351690-F1E884CD-126F-45F9-BE39-D91ABB488E7FQ38161550-B1FA44A1-CAD9-4C42-9F3E-3B5422B278FEQ38213838-2D6D839A-8CA1-40CA-A10B-AA699339D601Q38244247-D13DB85C-6CD4-43F5-93D5-18EE50DC8B91Q38269925-50A7E8B4-14CD-4250-88F4-AEA9D99D823AQ38513024-4F2A89B3-EBB9-4668-BCCD-C448991CCD1BQ38715233-5A7920EF-5005-44E5-8406-D6D07F07AD8BQ39115902-FB03ECE0-B90C-4CCF-A681-7BF9587E4474Q39178579-931F81E3-8035-47CE-8CF2-2CA62DDD4B02Q39209459-AB42899A-2515-48B7-8AF6-E26A392B4E7DQ39659132-E94D2806-3331-4778-A8C7-AB1729B3EAD6Q41244441-A370A041-CFDE-4BE0-9637-6E676621D06BQ42084547-B0FDE4DF-8DBB-4786-B055-20B37FF4B60FQ42183733-EC5AED8F-D523-41B8-A508-53CAFF8FA030Q45257868-AE2E16C0-110F-463C-94E1-E04990D9BE10Q46323541-DACF46BB-A088-4FAE-BDC1-F1C01B7C4EB5Q47142619-7BC3926A-7044-4D5A-96F6-8A644C7F16D3Q47659411-539E5630-CFFB-4061-BDCF-18952348C4FAQ47826150-32BC92C0-00DD-40AE-A77A-1D20AB3E81C1Q48201813-DC486067-B784-4F78-A964-84F08E4FFE07
P2860
Curcumin prevents aggregation in α-synuclein by increasing reconfiguration rate.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Curcumin prevents aggregation in α-synuclein by increasing reconfiguration rate.
@ast
Curcumin prevents aggregation in α-synuclein by increasing reconfiguration rate.
@en
type
label
Curcumin prevents aggregation in α-synuclein by increasing reconfiguration rate.
@ast
Curcumin prevents aggregation in α-synuclein by increasing reconfiguration rate.
@en
prefLabel
Curcumin prevents aggregation in α-synuclein by increasing reconfiguration rate.
@ast
Curcumin prevents aggregation in α-synuclein by increasing reconfiguration rate.
@en
P2860
P356
P1476
Curcumin prevents aggregation in α-synuclein by increasing reconfiguration rate
@en
P2093
Lisa J Lapidus
P2860
P304
P356
10.1074/JBC.M111.325548
P407
P50
P577
2012-01-20T00:00:00Z